Camurus AB (CAMX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Camurus AB (CAMX) has a cash flow conversion efficiency ratio of 0.060x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr255.43 Million ≈ $27.49 Million USD) by net assets (Skr4.24 Billion ≈ $455.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Camurus AB market capitalisation for the company's overall valuation and market capitalisation.
Camurus AB - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Camurus AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Camurus AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Camurus AB ranked by their cash flow conversion efficiency. Explore cash flow quality index of Camurus AB to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PI Industries Limited
NSE:PIIND
|
0.022x |
|
Secure Energy Services Inc.
TO:SES
|
0.241x |
|
Golar LNG Limited
F:G2O
|
0.040x |
|
Shanxi Coal International Energy Group Co Ltd
SHG:600546
|
0.129x |
|
Motor Oil (Hellas) Corinth Refineries S.A
AT:MOH
|
0.119x |
|
Tangshan Port Group Co Ltd
SHG:601000
|
0.028x |
|
Skyline Corporation
NYSE:SKY
|
0.063x |
|
Jb Financial
KO:175330
|
-0.126x |
Annual Cash Flow Conversion Efficiency for Camurus AB (2012–2025)
The table below shows the annual cash flow conversion efficiency of Camurus AB from 2012 to 2025. View latest Camurus AB stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr4.24 Billion ≈ $455.80 Million |
Skr869.30 Million ≈ $93.55 Million |
0.205x | +74.02% |
| 2024-12-31 | Skr3.29 Billion ≈ $354.02 Million |
Skr387.99 Million ≈ $41.75 Million |
0.118x | -70.98% |
| 2023-12-31 | Skr1.49 Billion ≈ $160.67 Million |
Skr606.88 Million ≈ $65.31 Million |
0.406x | +299.53% |
| 2022-12-31 | Skr994.67 Million ≈ $107.04 Million |
Skr101.20 Million ≈ $10.89 Million |
0.102x | +160.22% |
| 2021-12-31 | Skr848.91 Million ≈ $91.36 Million |
Skr-143.43 Million ≈ $-15.44 Million |
-0.169x | +40.05% |
| 2020-12-31 | Skr847.44 Million ≈ $91.20 Million |
Skr-238.83 Million ≈ $-25.70 Million |
-0.282x | +55.98% |
| 2019-12-31 | Skr631.63 Million ≈ $67.97 Million |
Skr-404.36 Million ≈ $-43.52 Million |
-0.640x | +41.06% |
| 2018-12-31 | Skr252.32 Million ≈ $27.15 Million |
Skr-274.08 Million ≈ $-29.50 Million |
-1.086x | -105.94% |
| 2017-12-31 | Skr385.00 Million ≈ $41.43 Million |
Skr-203.07 Million ≈ $-21.85 Million |
-0.527x | -43.27% |
| 2016-12-31 | Skr564.42 Million ≈ $60.74 Million |
Skr-207.79 Million ≈ $-22.36 Million |
-0.368x | -4068.62% |
| 2015-12-31 | Skr640.56 Million ≈ $68.93 Million |
Skr-5.66 Million ≈ $-608.78K |
-0.009x | -101.57% |
| 2014-12-31 | Skr123.46 Million ≈ $13.29 Million |
Skr69.43 Million ≈ $7.47 Million |
0.562x | -82.74% |
| 2013-12-31 | Skr50.05 Million ≈ $5.39 Million |
Skr163.06 Million ≈ $17.55 Million |
3.258x | +429.67% |
| 2012-12-31 | Skr40.21 Million ≈ $4.33 Million |
Skr24.73 Million ≈ $2.66 Million |
0.615x | -- |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more